PharmaEngine
4162.TWO
2.20 USD
0.03
+1.38%
p
Overview
Last close
2.20 usd
Market cap
311.44M usd
52 week high
3.68 usd
52 week low
2.13 usd
Target price
3.94 usd
Valuation
P/E
5.9135
Forward P/E
N/A
Price/Sales
3.8259
Price/Book Value
2.0134
Enterprise Value
130.63M usd
EV/Revenue
1.6048
EV/EBITDA
1.921
Key financials
Revenue TTM
81.40M usd
Gross Profit TTM
79.81M usd
EBITDA TTM
66.62M usd
Earnings per Share
0.37 usd
Dividend
0.2 usd
Total assets
195.59M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
